New drugs in the treatment of Hodgkin's disease

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Borchmann, P ^a   Schnell, R ^a   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bendamustine; Gemcitabine; Hodgkin's disease; Idarubicin; Immunotherapy; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOSIDE; BENDAMUSTINE; BLEOMYCIN; CHLORMETHINE; GEMCITABINE; IDARUBICIN; IMMUNOTOXIN; NAVELBINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ALOPECIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0032456477     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S103     Document Type: Conference Paper

References (29)

1. Agnarsson BA, Kadin ME. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's disease using fixed frozen tissue. Cancer 1989; 63: 2083-7.
2. Anger G, Fink R, Fleischer J et al. Vergleichsuntersuchung zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, der Lymphogranulomatose und dem Bronchialkarzinom. Dt. Gesundh.-Wesen 1975; 30:1280-5.
3. Arcamone F, Bermardi L, Giardino P et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9-diepidaunorubicin and their beta-anomers. Cancer Treat Rep 1976; 60: 829-34.
4. Benchekroun S, Chouflai Z, Harif M et al. Clinical study of Navelbine activity in Hodgkin's disease. Phase II study. In navelbine (Vinorelbine): Update and New Trends. Montrouge: Pierre Fabre Oncologie: Libbey Eurotext 1991; 261-4.
5. Binet S, Fellous A, Lataste H et al. In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin. Oncol 1989; 16 (2, Suppl 4): 5-8.
6. Bonfante V, Santoro A, Viviani S et al. Ifosfamide (IPX) and vinorelbine (VNR), an active regimen potentially effective in detecting sensitive relapses in Hodgkin's disease (HD). Proc Am Soc Clin Oncol 1997; 16: 33 (Meet 9a).
7. Bremer K, Roth W. Bendamustine, a low toxic nitrogen-mustard derivate with high efficacy in malignant lymphomas. Tumordiagn Ther 1996; 17:1-6.
8. Casazza AM, Pratesi G, Giuliani F et al. Antileukemic activity of 4-demethoxy- daunorubicin in mice. Tumouri 1980; 66: 549-64.
9. Delabie J, Ceuppens J L, Vandenberghe P et al. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's diseasederived cell lines. Blood 1993; 82: 2845-52.
10. Depierre A, Lemarie E, Dabouis G et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-8.
11. DeVita VT, Molloy Hubbard S. Hodgkin's disease. N Engl J Med 1993; 328: 560-5.
12. Devizzi L, Santaro A, Bonfante V et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5 (9): 817-20.
13. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: A new promising drug in Hodgkin's disease. Leuk Lymph 1996; 22: 409-14.
14. Di Marco A, Zunino E, Casazza AM. Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiot Chemother 1978; 23: 12-30.
15. Diehl V, Sieber M, Rüffer U et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997; 8 (2): 143-8.
16. Eghbali H. Phase II study of vinorelbine (navelbine) in previously treated Hodgkin's disease and non-Hodgkin's lymphoma. In Pierre Fabre Oncologie (ed): Navelbine (Vinorelbine): Update and New Trends. Montrouge: Libbey Eurotext 1991; 253-60.
17. Engert A, Diehl V, Schnell R et al. A phase I study of an antiCD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 15; 89 (2): 403-10.
18. Engert A, Schnell R, Kupper F et al. A phase II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high-grade non-Hodgkin's lymphoma. Lcuk Lymph 1997; 24 (5-6): 513-22.
19. Falini B, Pasqualucci L, Flenghi L et al. Anti-CD30 immunotoxins: Experimental and clinical studies. Abstracts of the Fourth International Symposium on Immunotoxins 1995; 160.
20. Ferme C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995; 6 (6): 517-8.
21. Green M. Gemcitabine safety overview. Semin Oncol 1996; 23 (5 Suppl 10): 32-5.
22. Hagemeister FB, Tannir N, McLaughlin P et al. MIME chemotherapy (methil-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 1986; 5: 556-9.
23. Hansen HH, Sorensen JB. Efficacy of single-agent gemcitabine in advanced non-small-cell lung cancer: A review. Semin Oncol 1997; 24 (Suppl 2): S7-38, S7-41.
24. Hartmann F, Renner C, Jung W et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 15; 89 (6): 2042-7.
25. Herold M, Anger G, Höche D, Kästner R. Vorläufige Ergebnisse einer zyklisch-alternierenden Chemotherapie (CVPP/DBVCy) bei fortgeschrittenem Morbus Hodgkin. Med Klin 1987; 82: 345-9.
26. Höche D, Wutke K, Anger G. Vergleichende Untersuchung zur Wirksamkeit des DBVcy-Protokolls (Daunoblastin, Bleomycin, Vincristin, Cytostasan) mit dem ABVD-Protokoll beim fortgeschrittenen Hodgkin-Lymphom. Arch Geschwulstforsch 1984; 4: 333-42.
27. Holliger P, Prospero T, Winter G. Diabodies: Small bivalent and bispecific antibody fragments. Proc Nail Acad Sei 1993; 90: 6444-8.
28. Hollingshead LM, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 42: 690-719.
29. Hsu SM, Jaffe ES. Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol I984; 82: 29-32.